Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01155492 · ClinicalTrials.gov registry record
Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease
A clinical trial, sponsored by Rush University Medical Center.
- Completed
- Registry status
- 43
- Enrollment target
NCT01155492: Completed study, sponsored by Rush University Medical Center.
NCT01155492 is a clinical trial that has completed, run by Rush University Medical Center. The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01155492 has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
The gut may be a portal of entry for agents that cause or contribute to the causes of Parkinson's disease (PD). The investigators are studying changes in the normal population of gut flora and in intestinal permeability and their associations with early PD.
Primary Outcome
Subjects consume a mixture of sugars (lactulose, sucrose), then collect urine for 24 hours. Sugar concentrations in the urine are assayed by gas chromatography.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2007-09 |
| Est. Completion | 2013-02 |
What the finished NCT01155492 record still lists
NCT01155492 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 43 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01155492 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01155492 about?
NCT01155492 is a clinical study titled "Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease". The gut may be a portal of entry for agents that cause or contribute to the causes of Parkinson's disease (PD). The investigators are studying changes in the normal population of gut flora and in intestinal permeability and their associations with early PD.
What is the current status of trial NCT01155492?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2007-09. Estimated completion is 2013-02.
Who is sponsoring clinical trial NCT01155492?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia